Bay 3670549

Phase 2

Bayer

Bay 3670549 is one of 38 therapeutic programs targeting Atrial Fibrillation. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Atrial FibrillationRecruiting

Atrial FibrillationPhase 2

Recruiting

Competition

Competitive Landscape

137 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Calquence

AstraZeneca

Preclinical

1 2

Rituxan

Coumadin

3 4

Brukinsa

BBeOne Medicines

Preclinical

1 5

Imbruvica

PPharmacyclics LLC.

Preclinical

1 6

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 7

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 8

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Statin

Bristol-Myers Squibb

Preclinical

1 10

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2Recruiting

Atrial Fibrillation

NCT07625215

Clinical

Trials by Indication[1]

Atrial Fibrillation1 trial

A Placebo-controlled, Parallel-group, Double Blind, Randomized, Multi-cohort Phase 2 Study to Investigate Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BAY 3670549 in Adult Participants With Atrial Fibrillation.

Recruiting· Bayer logo

Bayer·Phase 2·NCT07625215·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bay 3670549. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Bay 3670549. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Bayer

Bay 3670549

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Atrial Fibrillation1 trial

References

Drug Info

Quick Facts

Related News